Expert from Rutgers Cancer Institute of New Jersey available for comment on FDA approval for NALIRIFOX: a new first-line treatment for patients with metastatic pancreatic cancer

On February 13, 2024, the Food and Drug Administration approved NALIRIFOX, a combonation chemotherapy, for the first-line treatment of metastatic pancreatic adenocarcinoma.

Patrick Boland, MD, is a medical oncologist in the Gastrointestinal Oncology Program at Rutgers Cancer Institute of New Jersey and RWJBarnabas Health, New Jersey’s leading cancer program and only National Cancer Institute (NCI)-Designated Comprehensive Cancer Center. Dr. Boland’s clinical expertise includes gastrointestinal malignancies, colorectal cancer, anal cancer, gastroesophageal cancer, euroendocrine tumors and pancreatic cancer. He is available to share more about what this FDA approval means for patients.